▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #656 by analyst upside · 2026-08-12
PRTA
Prothena Corporation plc
Healthcare · Market Cap $473M · P/E 0x
ANALYST PRICE TARGET
+132.1%
implied upside to consensus target
Current Price $9.22
Consensus Target $21.4
Bull Target $36.0
Bear Target $8.0
Analysts Covering 5
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
1
Hold
2
Sell
0
52-Week Low $7.5
52-Week High $11.8
YTD Return +0.2%
FUNDAMENTALS
Market Cap $473M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.82
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $55M
Profit Margin -80.7%
52-WEEK RANGE
52-Week Low $7.5
52-Week High $11.8
Current Price $9.22
Bear Target $8.0
Bull Target $36.0
● Now $9.22 ● Target $21.4
TRADING DATA
Avg Volume 575K
YTD Return +0.2%
Analyst Count 5
Consensus Buy
Upside to Target +132.1%
Last Updated 2026-08-12

ANALYST SUMMARY

Prothena Corporation plc (PRTA) is currently trading at $9.22 with a Wall Street consensus price target of $21.4, implying potential upside of 132.1% over the next 12 months. 5 analysts currently cover PRTA, with a consensus rating of Buy - 60% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $36.0, while the most cautious has a target of $8.0.

PRTA operates in the Healthcare sector with a market capitalisation of $473M. The stock is up 0.2% year-to-date and is currently trading near the lower end of its 52-week range of $7.5 – $11.8.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

CRMD +105.5%
CorMedix Inc.
$573M · P/E 3.4x · Strong Buy
ZVRA +120.5%
Zevra Therapeutics, Inc.
$673M · P/E 12.2x · Buy
ABEO +166.4%
Abeona Therapeutics Inc.
$422M · P/E 7.8x · Buy
XFOR +171.0%
X4 Pharmaceuticals, Inc.
$424M · P/E 3.0x · Buy
QTTB +177.4%
Q32 Bio Inc.
$459M · P/E 4.9x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for PRTA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens - Reiterated
Market Outperform → Market Outperform 2026-05-08 Building track record
RBC Capital - Reiterated
Sector Perform → Sector Perform 2026-02-20 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2025-12-01 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-11-07 31% win rate (48 calls)
RBC Capital - Reiterated
Sector Perform → Sector Perform 2025-11-07 Building track record
Piper Sandler - Reiterated
Overweight → Overweight 2025-10-28 14% win rate (7 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2025-10-07 31% win rate (48 calls)
JMP Securities - Reiterated
Market Outperform → Market Outperform 2025-09-02 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
28
out of 100
Coverage depth
14/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →